Boston Scientific (BSX) Given New $33.00 Price Target at Morgan Stanley

Boston Scientific (NYSE:BSX) had its price objective lifted by equities research analysts at Morgan Stanley from $30.00 to $33.00 in a research note issued on Monday. The brokerage presently has an “overweight” rating on the medical equipment provider’s stock. Morgan Stanley’s price objective suggests a potential upside of 18.66% from the company’s previous close.

A number of other brokerages have also issued reports on BSX. Zacks Investment Research upgraded Boston Scientific from a “sell” rating to a “hold” rating in a research note on Tuesday, January 30th. Barclays restated a “buy” rating and set a $32.00 price objective on shares of Boston Scientific in a research report on Wednesday, January 10th. TheStreet upgraded Boston Scientific from a “c+” rating to a “b” rating in a research report on Thursday, January 18th. Jefferies Group restated a “neutral” rating on shares of Boston Scientific in a research report on Friday, February 2nd. Finally, ValuEngine lowered Boston Scientific from a “buy” rating to a “hold” rating in a research report on Wednesday, March 7th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $31.16.

How to Become a New Pot Stock Millionaire

Shares of Boston Scientific stock traded down $0.12 during mid-day trading on Monday, reaching $27.81. The company’s stock had a trading volume of 721,349 shares, compared to its average volume of 8,346,226. Boston Scientific has a 1-year low of $24.02 and a 1-year high of $29.93. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.68 and a quick ratio of 0.49. The stock has a market cap of $38,401.27, a price-to-earnings ratio of 398.57, a PEG ratio of 2.02 and a beta of 0.82.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.34 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.34. Boston Scientific had a return on equity of 24.27% and a net margin of 1.15%. The business had revenue of $2.41 billion during the quarter, compared to analyst estimates of $2.39 billion. During the same quarter in the prior year, the business posted $0.30 EPS. Boston Scientific’s revenue for the quarter was up 9.9% compared to the same quarter last year. equities analysts anticipate that Boston Scientific will post 1.37 earnings per share for the current fiscal year.

In related news, EVP Michael P. Phalen sold 15,835 shares of the stock in a transaction dated Friday, December 29th. The shares were sold at an average price of $25.25, for a total value of $399,833.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Kevin J. Ballinger sold 42,803 shares of the stock in a transaction dated Wednesday, March 14th. The shares were sold at an average price of $28.32, for a total transaction of $1,212,180.96. The disclosure for this sale can be found here. In the last ninety days, insiders sold 217,079 shares of company stock valued at $5,804,645. 0.74% of the stock is owned by insiders.

Large investors have recently made changes to their positions in the stock. Truewealth LLC bought a new position in shares of Boston Scientific in the 4th quarter valued at about $116,000. Icon Wealth Partners LLC bought a new stake in Boston Scientific in the fourth quarter worth about $117,000. Cerebellum GP LLC bought a new stake in Boston Scientific in the fourth quarter worth about $126,000. Delpha Capital Management LLC bought a new stake in Boston Scientific in the fourth quarter worth about $135,000. Finally, Valeo Financial Advisors LLC bought a new stake in Boston Scientific in the third quarter worth about $138,000. 91.04% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This report was posted by Ticker Report and is owned by of Ticker Report. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3277809/boston-scientific-bsx-given-new-33-00-price-target-at-morgan-stanley.html.

About Boston Scientific

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Analyst Recommendations for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Comparing BioFuel Energy  & William Lyon Homes
Comparing BioFuel Energy & William Lyon Homes
Analysts Anticipate LPL Financial  Will Post Earnings of $0.69 Per Share
Analysts Anticipate LPL Financial Will Post Earnings of $0.69 Per Share
Critical Contrast: Virtu Financial  versus The Competition
Critical Contrast: Virtu Financial versus The Competition
Head-To-Head Survey: Sprague Resources  vs. Genesis Energy
Head-To-Head Survey: Sprague Resources vs. Genesis Energy
National Research  vs. Cleveland BioLabs  Critical Survey
National Research vs. Cleveland BioLabs Critical Survey
OFCOIN  Trading Up 19.5% Over Last 7 Days
OFCOIN Trading Up 19.5% Over Last 7 Days


© 2006-2018 Ticker Report. Google+.